BACKGROUND: As therapies for systemic cancer improve and patients survive longer, the risk for brain metastases increases. We evaluated whether immune mechanisms are involved in the development of brain metastasis. METHODS: We conducted our studies using BALB/c mice bearing syngeneic 4T1 mammary adenocarcinoma cells in the mammary gland. RESULTS: The brains of mice bearing 4T1 tumors at day 14 had no detectable metastatic tumor cells but presented with marked accumulation of bone marrow-derived CD11b(+)Gr1(+) myeloid cells, which express high levels of inflammatory chemokines S100A8 and S100A9. In vitro, S100A9 attracts 4T1 cells through Toll-like receptor 4 and CD11b(+)Gr1(+) myeloid cells through Toll-like receptor 4 and the receptor for advanced glycation end-products. Systemic treatment of 4T1-bearing mice with anti-Gr1 (RB6-8C5) monoclonal antibody reduces accumulation of CD11b(+)Gr1(+) myeloid cells in the day-14 premetastatic brain as well as subsequent brain metastasis of 4T1 cells detected on day 30. Furthermore, treatment of 4T1 tumor-bearing mice with the cyclooxygenase-2 inhibitor celecoxib or genetic disruption of cyclooxygenase-2 in 4T1 cells inhibits the inflammatory chemokines and infiltration of CD11b(+)Gr1(+) myeloid cells in the premetastatic brain and subsequent formation of brain metastasis. CONCLUSIONS: Our results suggest that the primary tumor induces accumulation of CD11b(+)Gr1(+) myeloid cells in the brain to form "premetastatic soil" and inflammation mediators, such as S100A9, that attract additional myeloid cells as well as metastatic tumor cells. Celecoxib and anti-Gr1 treatment may be useful for blockade of these processes, thereby preventing brain metastasis in patients with breast cancer.
BACKGROUND: As therapies for systemic cancer improve and patients survive longer, the risk for brain metastases increases. We evaluated whether immune mechanisms are involved in the development of brain metastasis. METHODS: We conducted our studies using BALB/c mice bearing syngeneic 4T1 mammary adenocarcinoma cells in the mammary gland. RESULTS: The brains of mice bearing 4T1 tumors at day 14 had no detectable metastatic tumor cells but presented with marked accumulation of bone marrow-derived CD11b(+)Gr1(+) myeloid cells, which express high levels of inflammatory chemokines S100A8 and S100A9. In vitro, S100A9 attracts 4T1 cells through Toll-like receptor 4 and CD11b(+)Gr1(+) myeloid cells through Toll-like receptor 4 and the receptor for advanced glycation end-products. Systemic treatment of 4T1-bearing mice with anti-Gr1 (RB6-8C5) monoclonal antibody reduces accumulation of CD11b(+)Gr1(+) myeloid cells in the day-14 premetastatic brain as well as subsequent brain metastasis of 4T1 cells detected on day 30. Furthermore, treatment of 4T1 tumor-bearing mice with the cyclooxygenase-2 inhibitor celecoxib or genetic disruption of cyclooxygenase-2 in 4T1 cells inhibits the inflammatory chemokines and infiltration of CD11b(+)Gr1(+) myeloid cells in the premetastatic brain and subsequent formation of brain metastasis. CONCLUSIONS: Our results suggest that the primary tumor induces accumulation of CD11b(+)Gr1(+) myeloid cells in the brain to form "premetastatic soil" and inflammation mediators, such as S100A9, that attract additional myeloid cells as well as metastatic tumor cells. Celecoxib and anti-Gr1 treatment may be useful for blockade of these processes, thereby preventing brain metastasis in patients with breast cancer.
Authors: Andrea Facciabene; Xiaohui Peng; Ian S Hagemann; Klara Balint; Andrea Barchetti; Li-Ping Wang; Phyllis A Gimotty; C Blake Gilks; Priti Lal; Lin Zhang; George Coukos Journal: Nature Date: 2011-07-13 Impact factor: 49.962
Authors: Natasa Obermajer; Ravikumar Muthuswamy; Kunle Odunsi; Robert P Edwards; Pawel Kalinski Journal: Cancer Res Date: 2011-10-24 Impact factor: 12.701
Authors: Mitsugu Fujita; Gary Kohanbash; Wendy Fellows-Mayle; Ronald L Hamilton; Yoshihiro Komohara; Stacy A Decker; John R Ohlfest; Hideho Okada Journal: Cancer Res Date: 2011-02-15 Impact factor: 12.701
Authors: Bin-Zhi Qian; Jiufeng Li; Hui Zhang; Takanori Kitamura; Jinghang Zhang; Liam R Campion; Elizabeth A Kaiser; Linda A Snyder; Jeffrey W Pollard Journal: Nature Date: 2011-06-08 Impact factor: 49.962
Authors: Ethan S Srinivasan; Aaron C Tan; Carey K Anders; Ann Marie Pendergast; Dorothy A Sipkins; David M Ashley; Peter E Fecci; Mustafa Khasraw Journal: Mol Cancer Ther Date: 2021-01-05 Impact factor: 6.261
Authors: Hangyi H Yan; Jian Jiang; Yanli Pang; B R Achyut; Michael Lizardo; Xinhua Liang; Kent Hunter; Chand Khanna; Christine Hollander; Li Yang Journal: Cancer Res Date: 2015-10-19 Impact factor: 12.701